title: Cytotoxic aldehydes as possible markers for childhood cancer.
abstract: Concentrations of 22 known aldehydes (byproducts of lipid peroxidation), 5 acyloins, free and total carnitine and acylcarnitines were measured in plasma and urine obtained from pediatric patients with various forms of cancer before any treatment, and following treatment with doxorubicin or daunorubicin. Aldehydes, before the initiation of chemotherapy, were significantly elevated in cancer patients compared to controls. Aldehydes such as hexanal, heptanal, and malondialdehyde were strikingly higher in samples from cancer patients, while trans 4-cis-4-decenal was the prominent aldehyde in the blood of controls. In addition, in each form of cancer the pattern of aldehydes appeared to be unique when compared to controls, or to others forms of cancer. In cancer patients receiving chemotherapy there was a general trend toward a reduction 24 h after both the first and after the fifth doxorubicin dose. These changes however were not significant statistically due to large inter-patient variation. Free and total plasma carnitine levels remained in the normal range, and there were no abnormal acylcarnitines detected in urine. Possible hypotheses to explain the elevations in aldehydes, and the reasons for the changed aldehyde profiles in different forms of cancer are discussed.
authors.affiliation: Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Yazdanpanah
authors.forename: X
authors.initials: X
authors.lastname: Luo
authors.forename: R
authors.initials: R
authors.lastname: Lau
authors.forename: M
authors.initials: M
authors.lastname: Greenberg
authors.forename: L J
authors.initials: LJ
authors.lastname: Fisher
authors.forename: D C
authors.initials: DC
authors.lastname: Lehotay
mesh_terms: D000293:Adolescent; D000447:Aldehydes / Q000009:adverse effects* / Q000097:blood* / Q000652:urine; D014408:Biomarkers, Tumor / Q000009:adverse effects* / Q000097:blood* / Q000652:urine; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy; D002051:Burkitt Lymphoma / Q000097:blood / Q000188:drug therapy; D002331:Carnitine / Q000097:blood / Q000652:urine; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy; D015227:Lipid Peroxidation / Q000187:drug effects; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000188:drug therapy; D008315:Malondialdehyde / Q000097:blood; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy
chemical_list: D000447:Aldehydes; D014408:Biomarkers, Tumor; D008315:Malondialdehyde; D004317:Doxorubicin; C046204:heptanal; C010463:n-hexanal; D002331:Carnitine